logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9296820 B1

PDFFull Text
Date of Patent:
Mar. 29, 2016

Filed:

Nov. 05, 2004

Polynucleotides encoding anti-cd20 antigen binding molecules with increased fc receptor binding affinity and effector function

Applicants:

Pablo Umaña, Zurich, CH;

Peter Brünker, Hittnau, CH;

Claudia Ferrara Koller, Zug, CH;

Tobias Suter, Windisch, CH;

Ursula Püntener, Windisch, CH;

Ekkehard Mössner, Kreuzlingen, CH;

Inventors:

Pablo Umaña, Zurich, CH;

Peter Brünker, Hittnau, CH;

Claudia Ferrara Koller, Zug, CH;

Tobias Suter, Windisch, CH;

Ursula Püntener, Windisch, CH;

Ekkehard Mössner, Kreuzlingen, CH;

Assignee:

Roche GlycArt AG, Schlieren, CH;

Attorney:

Morrison & Foerster LLP

Primary Examiner:

Ron Schwadron

Int. Cl.
CPC ...
C12N 15/13 (2006.01); C12N 15/64 (2006.01); C12N 15/85 (2006.01); C12N 5/16 (2006.01); C07K 16/28 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/53 (2013.01); C07K 2317/56 (2013.01); C07K 2317/567 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); Y10S 530/808 (2013.01); Y10S 530/866 (2013.01); Y10S 530/867 (2013.01);
Abstract

The present invention relates to nucleic acids encoding anti-CD20 antigen binding molecules (ABMs). In particular embodiments, the present invention relates to nucleic acid encoding recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In some embodiments, the invention relates to an isolated polynucleotide comprising a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:40; SEQ ID NO:32; SEQ ID NO:56; and SEQ ID NO:60; and b) a sequence encoding a polypeptide having the sequence of SEQ ID NO:76. In addition, the present invention relates to vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Find Patent Forward Citations

Loading…